Leading research into ME/CFS

Company Name

The UK's first ME/CFS Biobank - driving biomedical research into ME/CFS

The UK ME/CFS Biobank

Driving clinical & biomedical research for recognition, diagnosis and treatment of ME/CFS.

The UK ME/CFS Biobank (UKMEB) is the first ME/CFS-specific biobank in Europe, and one of the first in the world. It has collected over 30,000 aliquots of blood from patients with ME/CFS and multiple sclerosis (as well as healthy controls), using a rigorous and consistent set of scientific protocols.

The UKMEB is run by the CureME research team at the London School of Hygiene and Tropical Medicine, and serves as the focal point for several major studies into ME/CFS, conducted by a committed research team with expertise in clinical epidemiology and laboratory science. It is overseen by a Steering Committee that includes patient representatives.

The UKMEB is committed to patient participation, and ensures that its research is always informed by and for the benefit of people with ME/CFS. It has contributed to highly significant research in immunology (including on NK and T cells and cytokine profiles), genetics, virology, clinical medicine, epidemiology and on the disabling effects of ME/CFS, and has released samples to researchers in the UK, Europe and America.

 

 

 

News
FAQs
About the biobank

How big a problem is ME/CFS in the UK?

1 in 500

People suffer from ME/CFS

4 : 1

ME/CFS female to male ratio

20,000

More people suffer from ME/CFS than MS

Myalgic Encephalomyelitis (ME) is a long-term (chronic), fluctuating, neurological condition that causes symptoms affecting many body systems, most commonly the nervous and immune systems. ME affects an estimated 250,000 people in the UK, and around 17 million people worldwide. People with ME/CFS experience severe, persistent fatigue associated with post-exertional malaise (the body’s inability to recover after expending even small amounts of energy), and the disease has also been referred to as Chronic Fatigue Syndrome.